A Tweetorial – Does PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer reduce recurrence?

Researchers developed a new multilayered microelectrode platform that can monitor neural activity throughout cerebral #organoids, improving long-term recording of 3D brain-like networks for neuroscience research and drug testing. 🔖 go.nature.com/4f8a9rP

A huge thank you goes out to all of the research nurses working tirelessly to help ELIPSE succeed!!! @Krish_Narahari @jonathananing @Heer_Lab @vishhanchanale @benchallacombe @BURSTurology @NorthBristolNHS @urorobot @nhsUHLG @UHSFT @SwanseabayNHS

Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri #ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.

Great to speak to you Adam. Focal therapy is an increasingly important field to rebalance the harms: benefit ratio in the debate around screening of prostate cancer @FocalSociety @UkFocal @IP_London

📣The £42M TRANSFORM study will get a £20M boost so that all eligible Black men are invited to join stage 2 📶Policies on healthcare for any group to be based on evidence 🇬🇧Govt also funding wider access to focal prostate therapy to ⬇️ harms of surgery & radiotherapy

👏Great news from DHSC supporting PCa research & better evidence for Black men 🔬 PCa screening policy must be built on robust evidence. 📈Expanding TRANSFORM will help generate evidence for earlier, fairer and safer screening gov.uk/government/news/major… @zubirahmed @DavidLammy

🚨 Save the date for the ⚡️ GRAND FINAL 🗓️ Tue 16 June #BURSTatBAUS26 🎤 THE RESEARCH X FACTOR- HEAD TO HEAD 🆚 🏆Who will win a share of £1000? 🍀May the most innovative solution win! 📍 Olympia | 🕝14:15-15:15 @BURSTurology x @TUF_tweets @BAUSurology

A huge thank you to our top recruiting sites this month! @GlasgowUrology @MrAlexLaird @RoyalDevonNHS @MrSteveBromage @StockportNHS @archie_hh @nhsfife @Heer_Lab @naeemsoomro @ace_aberdeen Find out more about PARTIAL here: w3.abdn.ac.uk/hsru/PARTIAL/P…

always so great to operate @CILR2026 (and celebrate my 50th) in beautiful rome with friends highlights: perfect RAPN by @NNHarke mindblowing imperative RAPN by @KarelDecaestec1 🧲RNU by @SimoneCrivella2💥IVC surgery by Giuseppe Simone & telesurgery 🇮🇹➡️🇨🇳 🙏🏽for the invitation

On multivariable analysis, three factors independently predicted recurrence: -- Prior recurrence: HR 1.75 (p=0.008) -- Multifocality: HR 1.49 (p=0.004) -- Grade G2 vs G1: HR 1.57 (p=0.018) One factor that did NOT predict recurrence: -- Tumor size: HR 1.08 (p=0.6)

IR NMIBC (Recurrent LG) of UK RCT- HIVEC-II, BOXIT, PHOTO, CALIBER suggest that despite 6 weekly induction chemotherapy nearly 50% develop recurrence at 5 yrs ⭐️Important bench mark to beat for upcoming RCT using surveillance as control shorturl.at/z8Jja

We’re one of 89 charities awarded a share of @NIHRresearch's £37m investment, supporting 800 early-career researchers! This will help our researchers at crucial stages of their careers and empowering them to drive future breakthroughs. Learn more: bit.ly/4aft801

We’re proud to be one of 89 charities awarded a share of @NIHRresearch £37m investment, supporting 800 early-career researchers. This funding helps our researchers at a crucial stage in their careers, driving breakthroughs. Find out more: bit.ly/4aft801 #Funding

Now look at our paper on TaHG patients treated with adequate BCG @KKBree et al., J Urol 2022 @pjhensley11 @niyatilobo Stage progression: 13% MIBC or metastasis: 6% BCG unresponsive: 13-14% Stage progression is 6x higher in TaHG than LG MIBC/metastasis risk is 3x higher than LG Make your own conclusions @MaxKates @LauraBukavinaMD @djmcconkey @joanfundi @drtanws @paolo_gontero @LAUrology_NL @ParamMariappan

This paper by @drtanws @heerlab @emmahall71 provides supporting evidence removing TaHG NMIBC from the IR NMIBC risk category When we properly define IR-NMIBC the way @IBCG_BladderCA recommends - LG disease only - and look at what happens to those patients across four RCTs (578 patients, contemporary treatment): Stage progression: 2% MIBC or metastasis: 2% Cancer-specific mortality: <1%

ELIPSE says a HUGE thank you to the team at The Christie for their AMAZING work!!!

🩺Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials by Wei Shen Tan...John D. Kelly et al buff.ly/59z3hSm 📢What does this study add? This study presents a pooled analysis of individual patient data from four randomized controlled trials involving intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC). The findings provide valuable estimates of recurrence and progression rates, which can inform clinical trial design, support accurate sample size calculations, and help optimize surveillance strategies for patients with IR-NMIBC. 🙌We thank the authors for trusting EUO with your work! @drtanws @UroDocAsh @NPortaStat @AlbertoMartini @ahmostafid @EmmaHall71 @Heer_Lab @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

An honour to be part of the European Association of Urology @Uroweb Scientific Congress Office. Months of planning to put together an exciting plan for #EAU27 In Amsterdam 🇳🇱. 👀 you there!

Turning data into better care - @BAUSurology National audits plenary *BREAKING NEWS* Results from BOOMERANG (recurrent UTIs), National BOO surgery audit, Penile # audit and EMPAST (testicular cancer) Monday 13.45 👀 Olympia

Know a nurse who goes above & beyond to transform patient care? Last chance to nominate them for the Urology Nurse of the Year Award. 🌟 Winner receives a £2,000 educational grant, trophy, and recognition at the BAUN Annual Awards Dinner. Nominate now: baun-2026.eventsair.site/awa…